Results 91 to 100 of about 1,208 (179)

Fragmentomics in Pediatric Genetics: A New Frontier for Non-invasive Diagnosis of Rare Congenital and Metabolic Disorders

Cell-free DNA (cfDNA) circulating in plasma is fragmented non-randomly, and the resulting patterns carry information about the cells and tissues from which the molecules were released.
Elena Moschüring-Alieva, Stefan Bittmann, Elisabeth Luchter   +2 more
core   +1 more source

Cancer treatment monitoring using cell-free DNA fragmentomes

Nature Communications
AbstractCirculating cell-free DNA (cfDNA) assays for monitoring individuals with cancer typically rely on prior identification of tumor-specific mutations. Here, we develop a tumor-independent and mutation-independent approach (DELFI-tumor fraction, DELFI-TF) using low-coverage whole genome sequencing to determine the cfDNA tumor fraction and validate ...
Iris van ’t Erve, Bahar Alipanahi, Keith Lumbard, Zachary L. Skidmore, Lorenzo Rinaldi, Laurel K. Millberg, Jacob Carey, Bryan Chesnick, Stephen Cristiano, Carter Portwood, Tony Wu, Erica Peters, Karen Bolhuis, Cornelis J. A. Punt, Jennifer Tom, Peter B. Bach, Nicholas C. Dracopoli, Gerrit A. Meijer, Robert B. Scharpf, Victor E. Velculescu, Remond J. A. Fijneman, Alessandro Leal   +21 more
openaire   +3 more sources

Abstract 3350: Cell-free DNA fragmentation patterns analyzed in over 15000 cancer patients reveal changes associated with tumor somatic mutations and result in improved sensitivity and specificity of somatic variant detection

, 2017
Background: Cell-free DNA (cfDNA) isolated from plasma consists of DNA fragments surviving clearance of dying cells and bloodstream trafficking. In cancer, these fragments carry the footprint of tumor somatic variation as well as its microenvironment ...
AmirAli Talasaz, Diana Abdueva, Helmy Eltoukhy, Darya Chudova   +3 more
core   +1 more source

Abstract B041: 5-Base cfDNA Fragmentomics Reveals Cancer-Associated Alterations in Gallbladder Cancer

Background: Gallbladder cancer (GBC) is a highly aggressive malignancy that is typically diagnosed at advanced stages due to nonspecific symptoms and a lack of screening strategies.
Yu-Tang Gao, Jill Koshiol, Xiaolin Wu, Xiongfong Chen, Yongmei Zhao, Michael Daniels, Ann Hsing, Ling Su   +7 more
core   +1 more source

Genomic and fragmentomic landscapes of cell-free DNA for early cancer detection

Nature Reviews Cancer
Genomic analyses of cell-free DNA (cfDNA) in plasma are enabling noninvasive blood-based biomarker approaches to cancer detection and disease monitoring. Current approaches for identification of circulating tumour DNA typically use targeted tumour-specific mutations or methylation analyses.
Daniel C. Bruhm, Nicholas A. Vulpescu, Zachariah H. Foda, Jillian Phallen, Robert B. Scharpf, Victor E. Velculescu   +5 more
openaire   +3 more sources

Gastric cancer detection by stomach chromatin–anchored salivary cell-free DNA fragmentomics

The current liquid biopsy paradigm rests mostly on plasma cell-free DNA (cfDNA), and only to a limited extent on other biofluids. Saliva is molecularly rich but difficult to use, as tumour signal must be separated from abundant background noise. Salivary
M. Constanza Camargo, Kyoung-Mee Kim, Jiyoung An, Irene Choi, David T. W. Wong, Matteo Pellegrini, Yingye Zheng, Fang Wei, Trinity Chan, Aaron Zander, Leila Syedmoradi, William Hsu, Akanksha Arora, David Elashoff, Karolina Kaczor-Urbanowicz, Ho Yeung Leung, Byung Hoon Min, Xiaojing Yang, Bradley Chan, Sung Kim, Sung Eun Oh, Wei Sun, Qianchuan He, Yong Kim, Jiaming Qiu, Jordan Cheng, Elliot Abemayor, Michael Weinstein, Neeti Swarup, Mohammad Arshad Aziz   +29 more
core   +1 more source

A cfDNA fragmentomics-based liquid biopsy assay for early detection of oral cancer

Background Early detection of oral cancer improves outcomes, but remains limited by the invasiveness and low sensitivity of current screening methods. Methods
Tao Ding, Wei Yang, Maoxi Zhong, Peng He, Yuan Jiang, Cuicui Liu, Weiwei Wang, Xinyue Hong   +7 more
core   +1 more source

Fragmentomics of plasma mitochondrial and nuclear DNA inform prognosis in COVID-19 patients with critical symptoms

Background The mortality rate of COVID-19 patients with critical symptoms is reported to be 40.5%. Early identification of patients with poor progression in the critical cohort is essential to timely clinical intervention and reduction of mortality ...
Fang Zheng, Xin Jin, Yeqin Wang, Wenwen Zhou, Rong Xie, Ye Tao, Jinjin Xu, Rijing Ou, Yilin Chen, Yu Lin, Yong Bai, Yuxue Luo, Haiqiang Zhang, Yan Zhang, Lingguo Li, Yan Jin, Ruokai Qu, Fanjun Cheng   +17 more
core   +1 more source

Protein-oligopeptide fragmentomics

, 2008
8
openaire   +2 more sources

A method of comprehensive sequencing analysis of the small RNA fragmentome (RiboMarker)

RNA
Circulating cell-free nucleic acids (cfDNA and cfRNA) found in blood and other biofluids are promising biomarkers for cancer. However, current methods exploiting tumor-derived cfDNA (ctDNA) are not sensitive enough in detecting minimal residual disease and early stages of cancer when it is more treatable.
Rachel C. Clark, Aidan C. Manning, Jonathan M. Howard, Sergio Barberán-Soler, Sergei A. Kazakov   +4 more
openaire   +2 more sources